Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Lucarelli, Giuseppe ^a   Ditonno, Pasquale ^a   Bettocchi, Carlo ^a   Vavallo, Antonio ^a   Rutigliano, Monica ^a   Galleggiante, Vanessa ^a   Larocca, Angela Maria Vittoria ^a   Castellano, Giuseppe ^a   Gesualdo, Loreto ^a   Grandaliano, Giuseppe ^b   Selvaggi, Francesco Paolo ^a   Battaglia, Michele ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; MUCIN 1;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARTIAL NEPHRECTOMY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; VISCERAL METASTASIS; YOUNG ADULT; BLOOD; CARCINOMA, RENAL CELL; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; KIDNEY NEOPLASMS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; CA-125 ANTIGEN; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUCIN-1; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84896917619     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/689795     Document Type: Article

References (29)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2013. Cancer Journal for Clinicians 2013 63 1 11 30
2. Motzer R. J., Bander N. H., Nanus D. M., Medical progress: renal-cell carcinoma. The New England Journal of Medicine 1996 335 12 865 875 2-s2.0-0030593729 10.1056/NEJM199609193351207
3. Pantuck A. J., Zisman A., Belldegrun A. S., The changing natural history of renal cell carcinoma. Journal of Urology 2001 166 5 1611 1623
4. Kim S. P., Weight C. J., Leibovich B. C., Thompson R. H., Costello B. A., Cheville J. C., Lohse C. M., Boorjian S. A., Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 2011 78 5 1101 1106 2-s2.0-80455174611 10.1016/j.urology.2011.05.012
5. Tunuguntla H. S., Jorda M., Diagnostic and prognostic molecular markers in renal cell carcinoma. Journal of Urology 2008 179 6 2096 2102 2-s2.0-43049109844 10.1016/j.juro.2008.01.083
6. Bui M. H., Visapaa H., Seligson D., Kim H., Han K.-R., Huang Y., Horvath S., Stanbridge E. J., Palotie A., Figlin R. A., Belldegrun A. S., Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. Journal of Urology 2004 171 6 2461 2466 2-s2.0-2442490125 10.1097/01.ju.0000116444.08690.e2
7. Klatte T., Seligson D. B., Riggs S. B., Leppert J. T., Berkman M. K., Kleid M. D., Yu H., Kabbinavar F. F., Pantuck A. J., Belldegrun A. S., Hypoxia-inducible factor 1 α in clear cell renal cell carcinoma. Clinical Cancer Research 2007 13 24 7388 7393 2-s2.0-37549043546 10.1158/1078-0432.CCR- 07-0411
8. Jacobsen J., Rasmuson T., Grankvist K., Ljungberg B., Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. Journal of Urology 2000 163 1 343 347 2-s2.0-0033992036
9. Johnson T. V., Abbasi A., Owen-Smith A., Young A., Ogan K., Pattaras J., Nieh P., Marshall F. F., Master V. A., Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. Journal of Urology 2010 183 2 480 485 2-s2.0-73749086365 10.1016/j.juro.2009.10.014
10. de Martino T Klatte C Seemann M., Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). BJU International 2013 111 8 E348 E353 10.1111/bju.12067
11. Sobin L. H., Gospodarowicz M. K., Wittekind C., International Union Against Cancer (UICC) TNM Classification of Malignant Tumours 2010 7th New York, NY, USA Wiley-Liss
12. Lucarelli G., Fanelli M., Larocca A. M. V., Germinario C. A., Rutigliano M., Vavallo A., Selvaggi F. P., Bettocchi C., Battaglia M., Ditonno P., Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 2012 72 15 1611 1621 2-s2.0-84858192691 10.1002/pros.22514
13. Lucarelli G., Ditonno P., Bettocchi C., Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. Future Oncology 2013 9 6 899 907
14. Lucarelli G., Rutigliano M., Bettocchi C., Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer. Journal of Urology 2013 190 6 2271 2277
15. Grankvist K., Ljungberg B., Rasmuson T., Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. International Journal of Cancer 1997 74 2 233 2366
16. Bamias A., Chorti M., Deliveliotis C., Trakas N., Skolarikos A., Protogerou B., Legaki S., Tsakalou G., Tamvakis N., Dimopoulos M. A., Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma. Urology 2003 62 2 368 373 2-s2.0-0042623891 10.1016/S0090-4295(03) 00264-4
17. Rasmuson T., Grankvist K., Ljungberg B., Serum β 2-microglobulin and prognosis of patients with renal cell carcinoma. Acta Oncologica 1996 35 4 479 482 2-s2.0-0029886998
18. Romero J. M., Aptsiauri N., Vazquez F., Cozar J. M., Canton J., Cabrera T., Tallada M., Garrido F., Ruiz-Cabello F., Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens 2006 68 4 303 310 2-s2.0-33749580272 10.1111/j.1399-0039.2006.00673.x
19. Sáenz-López P., Gouttefangeas C., Hennenlotter J., Concha A., Maleno I., Ruiz-Cabello F., Cózar J. M., Tallada M., Stenzl A., Rammensee H.-G., Garrido F., Cabrera T., Higher HLA class i expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens 2010 75 2 110 118 2-s2.0-73949111644 10.1111/j.1399-0039.2009.01409.x
20. Nomura T., Huang W.-C., Zhau H. E., Wu D., Xie Z., Mimata H., Zayzafoon M., Young A. N., Marshall F. F., Weitzmann M. N., Chung L. W. K., β 2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clinical Cancer Research 2006 12 24 7294 7305 2-s2.0-33846261554 10.1158/1078-0432.CCR-06-2060
21. Nomura T., Huang W.-C., Seo S., Zhau H. E., Mimata H., Chung L. W. K., Targeting β 2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. Journal of Urology 2007 178 1 292 300 2-s2.0-34250156009 10.1016/j.juro.2007.03.007
22. Leroy X., Copin M.-C., Devisme L., Buisine M.-P., Aubert J.-P., Gosselin B., Porchet N., Expression of human mucin genes in normal kidney and renal cell carcinoma. Histopathology 2002 40 5 450 457 2-s2.0-0036093805 10.1046/j.1365-2559.2002.01408.x
23. Schroeder J. A., Thompson M. C., Gardner M. M., Gendler S. J., Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. The Journal of Biological Chemistry 2001 276 16 13057 13064 2-s2.0-0035918199 10.1074/jbc.M011248200
24. Fujita K., Denda K., Yamamoto M., Matsumoto T., Fujime M., Irimura T., Expression of MUC1 mucins inversely correlated with post surgical survival of renal cell carcinoma patients. British Journal of Cancer 1999 80 1-2 301 308 2-s2.0-0032897021 10.1038/sj.bjc.6690355
25. Kraus S., Abel P. D., Nachtmann C., Weidner W., Stamp G. W. H., Chaudhary K. S., Mitchell S. E., Franke F. E., Lalani E.-N., MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Human Pathology 2002 33 1 60 67 2-s2.0-0036158113 10.1053/hupa.2002.29682
26. Leroy X., Zerimech F., Zini L., Copin M.-C., Buisine M.-P., Gosselin B., Aubert J.-P., Porchet N., MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. American Journal of Clinical Pathology 2002 118 1 47 51 2-s2.0-0036307815 10.1309/1F99-BPDY-7DHH- 9G97
27. Langner C., Ratschek M., Rehak P., Schips L., Zigeuner R., Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Modern Pathology 2004 17 2 180 188 2-s2.0-4644229471 10.1038/modpathol.3800032
28. Aubert S., Fauquette V., Hémon B., Lepoivre R., Briez N., Bernard D., Van Seuningen I., Leroy X., Perrais M., MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Research 2009 69 14 5707 5715 2-s2.0-67650999815 10.1158/0008-5472.CAN- 08-4905
29. Briasoulis E., Pentheroudakis G., Letsa I., Pavlidis N., A retrospective analysis of serum CA 15-3 concentrations in patients with localised or metastatic renal cancer and its impact on prognosis and follow-up. A single-centre experience. UroOncology 2002 2 4 179 184 2-s2.0-0036970870 10.1080/1561095021000064299